| Name | Abeprazan hydrochloride |
| Description | Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation. Abeprazan hydrochloride is a proton pump inhibitor (PPI) that acts by reducing gastric acid production and is used to treat gastric acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers. |
| In vitro | The mechanism of action of Abeprazan hydrochloride involves reversible binding to H+, K+-ATPase, and, unlike PPIs, it does not require an acidic environment for activation [1]. |
| In vivo | Abeprazan hydrochloride effectively suppresses acid secretion in a dose-responsive manner, demonstrating equal or superior efficacy to vonoprazan, an established P-CAB, across multiple in vivo studies including pylorus-ligated rats, lumen-perfused rat models, and Heidenhain pouch dog models[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.48 mM), Sonication is recommended.
DMSO : 40 mg/mL (89.51 mM), Sonication is recommended.
|
| Keywords | Protonpump | Proton pump | Fexuprazan Hydrochloride | DWP-14012 Hydrochloride | DWP14012 Hydrochloride | DWP 14012 Hydrochloride | Abeprazan Hydrochloride |
| Inhibitors Related | Ilaprazole | Omeprazole Sodium | Chebulinic acid | Esomeprazole | Pantoprazole sodium | Esomeprazole Magnesium | Pantoprazole Sodium Hydrate | Vonoprazan Fumarate | Lansoprazole | Zinc pyrithione | Esomeprazole Sodium | Pantoprazole |
| Related Compound Libraries | Exosome Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
United States
